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Abstract 
Despite evidence for its efficacy and effectiveness, the use of medication for the 
treatment of ADHD remains controversial. Little is known about the factors that 
influence clinicians’ decisions to use medication for ADHD. Here we present initial 
data on the attitudes of prescribing clinicians from the Influences on Prescribing for 
ADHD Questionnaire (IPAQ) – a new clinician-completed, 40-item scale.  The eight 
IPAQ subscales cover attitudes towards; (i) treatment outcome optimisation, (ii) the 
use of rule based over more informal approaches, (iii) side effects, (iv) symptoms 
control as the primary goal of treatment, (v)  the influence of external pressure on 
medication related decisions, (vi) the value of taking the child’s views into account, 
(vii) long term medication use and (viii) the value of psychosocial approaches for the 
treatment of ADHD.  Sixty-eight clinicians from Belgium and the UK took part. All 
subscales had acceptable levels of internal reliability (Chronbach’s alpha 
= 0.62−0.78). Overall, clinicians reported taking a rule-based approach to prescribing 
with a focus on treatment optimisation, taking the child’s view into account and 
valuing psycho-social approaches. They focused on treating broader patterns of 
impairment, but were wary of the potential side effects and long-term treatment. 
Psychiatrists scored high on their focus on symptom control and preference for long-
term medication use, while paediatricians reported using more rule-based approaches. 
We identified four distinctive response profiles: (i) pro-psychosocial; (ii) medication 
focused; (iii) unsystematic; and (iv) response optimizers. Future larger scale studies 
are required to replicate these profiles and to explore their relationship with 
prescribing behaviour and treatment outcomes. 
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Introduction 
Attention Deficit/Hyperactivity Disorder (ADHD) is an early onset and debilitating 
mental health condition, which can persist across the life span [1]. At its core, is a persistent 
and pervasive pattern of inattention and/or hyperactivity and impulsiveness. It often 
overlaps with other conditions (e.g., oppositional defiant disorder, conduct disorder, anxiety, 
and reading problems [2, 3] and causes significant impairment across multiple functional 
domains [4]. Children with ADHD are more likely to fail at school and to go on to be 
unemployed [5, 6],  to be involved in crime [7], to use illegal substances [1]  and to suffer 
from other comorbid mental health problems[8]. Moreover, ADHD also significantly 
impacts on patients’ families leading to disrupted parental marriages and parent-child 
relationships, as well as increased levels of parental stress [9]. The condition also affects 
communities and is associated with substantial economic and health care burden [10, 11]. 
Accordingly, effective management of ADHD is a major health policy goal across nations.  
While behavioural interventions are recommended as first-line treatment in very 
young or less severe cases, multi-modal approaches combining pharmacological and non-
pharmacological therapies are generally advised by clinical guidelines for the treatment of 
ADHD [12-16]. Evidence from randomised controlled trials supports stimulant medications 
such as methylphenidate and amphetamines [17-19] as well as non-stimulants such as 
atomoxetine, clonidine extended-release (ER) and guanfacine extended-release (ER), as 
efficacious medical treatments for ADHD [20-24]. These treatments reduce the level of 
core ADHD symptoms giving a good short-term clinical response in between 70 and 80 
percent of patients [18, 25]. Building on this evidence base, clinical guidelines have made 
recommendations about the initiation, continuation, switching or stopping of medications 
for ADHD [12-16, 26].  
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Despite the empirical evidence and published guidelines which highlight the value 
of medication for the treatment of individuals with ADHD, ultimately, the decision to use 
medication remains with the clinician. In making treatment decisions, the clinician has to 
weigh-up different (and sometimes competing) formal (e.g., medical guidelines) and 
informal (parents, teachers, patients) sources of information, influences and priorities when 
determining whether, when and how to initiate medication, whether to alter the medication 
regime during treatment, and finally, when to stop medication. We have recently completed 
a series of semi-structured interviews with child psychiatrists, and paediatricians (in 
Belgium and England) exploring the range of factors that might influence diagnostic and 
treatment-related decisions [27]. On the basis of these findings we identified a number of 
factors likely to influence treatment  and medication practice in relation to ADHD. These 
form the basis for a new questionnaire – the Influences on Prescribing for ADHD 
Questionnaire (IPAQ) (for a full description, see Methods section).  
In the current paper we examine the reliability of the IPAQ subscales; explore  the 
relationship between IPAQ scores and clinicians’ background and characteristics – 
including their gender, age, experience with ADHD, professional affiliation and their 
country of work (England or Belgium);  and generate  an initial set of clinician profiles 
relating specifically to attitudes towards prescribing medication for children with ADHD.  
 
Method 
Measure 
The IPAQ was developed on the basis of the key themes derived from qualitative 
analysis of semi-structured interview data carried out in the Decisions Regarding ADHD 
Management (DRAMa) study [27]. The DRAMa study focused on the uncertainties and 
complexities in assessment, diagnosis and treatment of ADHD from the clinician’s point of 
view (for more detailed information and results, please refer to Kovshoff et al [27]. On the 
6 
 
basis of inductive thematic analysis of 50 interviews with consultant psychiatrists and 
paediatricians, ten themes were identified that related to medication-related decision 
making. For the purpose of designing the questionnaire, these qualitative data were 
supplemented by a review of current evidence-based ADHD guidelines [12-16, 28].  
Initially 70 items were generated, covering ten themes in relation to treatment initiation, 
treatment switching and treatment termination. All of the items were rated on a likert scale 
of 0 (not at all important) to 6 (extremely important) and a separate score was generated for 
each subscale. 
The original 70 item clinician-completed questionnaire was analysed to ensure 
that all subscales had adequate internal consistency. Following, the measure was 
reduced to a 40-item scale with eight subscales and five items making up each 
subscale. These cover attitudes in relation to; (i) treatment outcome optimisation, (ii) 
the use of rule based over more informal approaches, (iii) side effects, (iv) symptoms 
control as the primary goal of treatment, (v)  the influence of external pressure on 
medication-related decisions, (vi) the value of taking the child’s views into account, 
(vii) lon- term medication use and (viii) the value of psychosocial approaches for the 
treatment of ADHD.   
 (i) Attitudes to optimising outcomes measures the extent to which prescribing 
clinicians are motivated to achieve as much symptom reduction and functional 
improvement as they can, or whether they are satisfied with a sufficient “degree of 
improvement” that may nevertheless be suboptimal.  
 (ii) Rule based approach focuses on issues relating to the more general 
clinical style of the respondent. It measures how closely clinicians follow clinical 
guidelines and their recommendations for prescribing medication to make their 
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treatment decisions or whether they employ a more flexible, individualized, and 
experience based approach.  
(iii) Tolerance of side effects assesses clinicians’ sensitivity to the types of 
adverse events  typically associated with ADHD medications [31-35].  
(iv) Focus on symptoms: This covers two elements; first the focus on 
symptoms as opposed to impairment and second, the focus on symptoms as opposed 
to underlying causes. While the diagnosis of ADHD requires both symptom and 
impairment criteria to be met, it remains unclear how focused clinicians are on 
symptom reduction as opposed to improvements of daily functioning when judging 
the effectiveness of medication. With regards to the causal nature of ADHD, the 
phenomenological approach that underpins ADHD diagnosis in current systems 
makes no reference to underlying reasons for the behaviour (i.e., genetics, 
environment or neurobiology). However, the finding from Kovshoff et al [27] 
highlighted that clinicians differentiated between biological ADHD, where there was 
apparent neurobiological dysfunction and family heritability, and non-biological 
ADHD which they judged as being due to environmental factors. 
(v) Influence of external pressure subscale measures the role of external 
influences on decision making. In some situations, parents or teachers may place 
clinicians under pressure to make a diagnosis and treat a child, even when the 
clinician believes treatment is unnecessary. Alternatively, clinicians may be 
convinced of the need for medication, but not always try to persuade parents who may 
be reluctant to medicate their child. They may also be impervious to external pressure 
to prescribe in cases where they do not believe it would be beneficial for the child.  
(vi) Importance of the child’s views. As the need for medication is primarily 
determined by adults, little is known about the extent to which the views of children 
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are taken into account when making treatment decisions. The items in this subscale 
focus on whether the child’s views are perceived to influence prescribing practice, 
and the extent to which these views may be overridden by those of the adults.  
  (vii) Long-term use of medication. Some models of ADHD highlight its status 
as a lifelong condition that requires long-term use of medication for its effective 
treatment. Alongside these, a number of concerns have been raised in the literature 
about the potential long-term chronic use of stimulants [29] not least in relation to 
brain development [30-32]. Unfortunately, there are little or no data from long term 
RCTs that would allow the evaluation of these claims and clinicians are left to 
manage this uncertainty without an evidence base to guide them. Using this subscale 
we attempted to quantify clinicians’ willingness to use medication long term.  
(viii) Importance of psychosocial treatments:  Published guidelines 
recommend the use of psychosocial interventions prior to medication trials. Moreover, 
many parents and clinicians are often hesitant about using medication and look for 
effective alternatives to medication for the treatment of ADHD. Thus, the extent to 
which clinicians value psychosocial treatments relative to medication as an effective 
treatment for ADHD was judged likely to be an important factor in determining 
clinicians’ decision to use medication. 
–—–—–—–—–—–—–—–—–—–—–—–—–— 
Table 1 about here 
–—–—–—–—–—–—–—–—–—–—–—–—–— 
Multiple items were designed to cover each theme/subscale. In each putative 
subscale ambiguity and overlap were avoided as far as possible. For the Flemish version of 
the IPAQ, items were translated from English to Dutch and back-translated following 
standard procedures.  
Procedure 
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Participant Recruitment. In the South of England, participants were originally 
recruited for a linked study (Kovshoff et al [27]– see Measures section for a description) via 
email through the complete child psychiatrist (n = 79) and paediatrician (n = 49) practice 
register list for the region. Twenty-two (13 psychiatrists and 9 paediatricians) opted to 
participate in the first phase of the project and all 22 were re-contacted and asked to 
participate in the present research. Additional participants were also recruited through 
approaching professional groups of clinicians specialising in ADHD. In Belgium, 
participants were originally recruited for the same linked study listed above via the 
complete child psychiatrist (n = 187) and paediatrician (paediatricians: n = 758, child 
neurologists: n= 35) practice register list. Of these clinicians, 149 were randomly selected 
via an internet-based randomization procedure and invited to participate in the interview 
study. Thirty (15 psychiatrists and 15 paediatricians) of 149 opted to participate in the first 
phase of the project and 29 of 30 also participated in the present research. Additional 
participants (n = 18, of which 8 child psychiatrists and 10 paediatricians) were also 
randomly recruited via the same child psychiatrist and paediatrician practice register list. 
Clinicians were sent the IPAQ along with a participant information sheet, consent form, and 
stamped addressed envelope to return the questionnaire.  
Data analysis 
Cronbach’s alpha coefficients were computed to assess the internal consistency of 
each IPAQ subscale. On the basis of the internal consistency analysis (Cronbach’s alphas 
were calculated for each domain and the scale overall), 30 individual items and two themes 
were dropped. The final questionnaire data that were used for the remaining analyses 
reported in the current paper consist of responses to questions grouped into eight 
themes/subscales consisting of five items per subscale for a total of 40 items (see Table 1).  
10 
 
 Means and standard deviations for each of the eight final subscales were computed, 
and Pearson correlation coefficients were employed to assess the correlation values between 
individual subscales. Additionally, Pearson correlation coefficients and t-tests were 
computed to explore the associations between the IPAQ subscale scores and clinician 
characteristics including gender, country of practice (UK or Belgium), clinician type 
(psychiatrist or paediatrician/child neurologist), total years practicing medicine, and total 
years practicing as a consultant specialising in ADHD. Finally, K-means cluster analysis 
was used to determine the best fit cluster solution amongst the data. 
 
Results 
Participant characteristics. A total of 68 participants returned completed IPAQ 
questionnaires including 47 participants from Flanders, Belgium and 21 from the South of 
England.  The sample included 34 child psychiatrists and 34 paediatricians/child 
neurologists. Forty participants were female. The average number of years since 
qualification as a medical practitioner for the entire group was 17.34 (SD = 10.47; 15.23 
(SD = 9.28) for psychiatrists and 20.50 (SD = 11.59) for paediatricians). The mean number 
of years of experience working at consultant level with children with ADHD for the full 
sample was 14.95 (SD = 12.65); 10.10 (SD = 9.18) for psychiatrists and 20.09 (SD = 14.95) 
for paediatricians). There was a significant group difference for number of years working in 
a senior consultant role, with paediatricians having worked more years in the field t(64) = -
3.47, p = .001. There were no significant between-group differences for total number of 
years in medical practice. 
Internal consistency. Cronbach alpha coefficients on the final eight subscales are 
shown in Table 1. These ranged from .62 to .78, indicating acceptable levels of internal 
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consistency and reliability. The reliability of sub-scales was not improved by removing 
individual specific items.  
–—–—–—–—–—–—–—–—–—–—–—–—–— 
Table 2 about here 
–—–—–—–—–—–—–—–—–—–—–—–—–— 
Descriptive statistics. Subscale mean scores ranged from 0 to 30 (see table 2). The 
subscale with the highest mean score was rule based approach  (M = 22.22, SD 4.82), 
indicating that the majority of clinicians regarded following guidelines and regulations with 
regards to medicating patients of importance to their practice. This includes ensuring 
patients had a confirmed diagnoses and carefully checking for contra-indications before 
prescribing. Clinicians also reported that optimising outcomes was an important treatment 
aim, rather than being satisfied with some improvement (M = 19; SD = 4.74). The 
importance of children’s’ views was regarded as significantly guiding their decisions (M = 
18.08, SD = 4.12) and psychosocial treatments were seen as an important first step in 
treatment (M = 16.85, SD = 5.36). The lowest mean score was found for the focus on 
symptoms subscale (M = 8.84; SD = 4.12). This suggests that clinicians are more concerned 
with levels of impairment and/or the causes of the patient’s ADHD behaviour than 
symptoms. A low score was also seen for tolerance of side effects (M = 10.85, SD = 4.82), 
which suggests that clinicians are in general concerned about side-effects and these exert an 
influence on their prescribing behaviours. External pressure from parents or teachers is not 
regarded as having a strong influence by clinicians on their practice (M = 11.85, SD = 4.75) 
and clinicians are predominantly in favour of stopping treatment as soon as it seems feasible, 
rather than treating ADHD with medication over the long term (M =  13.15, SD = 5.15). 
–—–—–—–—–—–—–—–—–—–—–—–—–— 
Table 3 about here 
–—–—–—–—–—–—–—–—–—–—–—–—–— 
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Subscale inter-correlations. Pearson correlation coefficients indicated that six of 
the eight subscales were significantly correlated with other subscales. Significant 
correlations ranged from r = .29 to r =.44 and included positive associations between rule 
based approaches and importance of psychosocial treatments (r = .29, p = .016); and 
tolerance of side effects and long term use of medication (r = .39, p = .001). Negative 
associations were found between the rule based approaches subscale and the tolerance of 
side effects (r = -.40, p = .001) and influence of external pressure (r = -.44; p <.001) 
subscales. Negative correlations were also found between importance of psychosocial 
interventions and tolerance of side effects (r = -.30; p <.012), focus on symptoms (r =  -.29; 
p <.018), and long term use of medication (r = -.37; p =.002) subscales. The attitudes 
towards optimising outcomes and importance of the child’s views subscales were not 
correlated with other subscales. 
Relationships between IPAQ subscales and clinician characteristics. There was 
a significant gender effect on the attitudes to optimising treatment subscale score with 
female clinicians reporting more positive attitudes to optimising than male clinicians t(66) = 
-2.60, p = .011. There was also an effect of country of practice and the rule based approach 
and influence of external pressure subscales. Belgian participants used more rule based 
approaches t(66) = -3.17, p = .002 and showed a trend towards higher scores on the 
attitudes to optimising subscale t(66) = -1.98, p = .052. UK participants were more 
influenced by external pressure t(66)= 5.79, p = <.001. Clinician type (psychiatrist or 
paediatrician/child neurologist) was related to the rule based approaches, tolerance of  side 
effects, and long term use of medication subscales. Paediatricians reported using a more 
systematic and rule based approach t(66)= -2.48, p = .016 relative to their psychiatric 
colleagues. Psychiatrists were found to be more tolerant of side effects t(66)= -2.51, p =.015 
and prefer longer term courses of medication t(66)=2.60, p =.011. Finally, a positive 
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correlation was found between the focus on symptoms subscale and the total length of times 
clinicians were in medical practice (r = .34, p = .012), showing that less experienced and 
younger clinicians are likely to be more  interested in improving functioning compared to 
their more experienced peers.  
Preliminary classification of clinicians into different clusters.  K-means cluster 
solutions with two to five cluster factors were analysed and visually inspected to determine 
the best fit model which included roughly equal numbers of participants in each group and 
fit with hypotheses that there may be separate groups of clinicians who showed clear 
preferences for medication or psychosocial treatments for ADHD. The best fit model for the 
current data included four clusters with roughly equal numbers of participants in each group. 
An ANOVA determined that a significant interaction exists between the four cluster groups 
and mean IPAQ subscale scores F(21, 448) = 11.06, p < 0.001. Post hoc tests using the 
Bonferroni correction revealed significant differences between the four cluster groups and 
scores on the eight IPAQ subscales. These difference scores and significance levels are 
summarised in Table 4. 
–—–—–—–—–—–—–—–—–—–—–—–—–— 
Figure 1 about here 
–—–—–—–—–—–—–—–—–—–—–—–—–— 
Cluster 1 (n=15), reported being least tolerant of the putative side effects of 
medication,  placed the most importance on the child’s views, and were the most supportive 
of psychosocial interventions. Because of this profile we labelled this group pro 
psychosocial. The second cluster (n=18)  focused more on treating ADHD symptoms and 
were most positive about longer term medication hence we labelled this group medication 
focused. They were also most tolerant about side effects. Cluster 3 (n=15), which we 
labelled unsystematic, was distinguished from the other three clusters in their reports of 
using the least systematic approach. Finally, the fourth cluster (n=20; response optimisers) 
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had the highest score on the optimising subscale, and were least influenced by external 
pressure. Figure 1 illustrates the cluster patterns for each IPAQ subscale. 
–—–—–—–—–—–—–—–—–—–—–—–—–— 
Table 4 about here 
–—–—–—–—–—–—–—–—–—–—–—–—–— 
Discussion 
 We have presented initial data from the IPAQ - describing clinicians’ attitudes 
to prescribing medication for ADHD.  All of the subscales were internally consistent 
and reliable. Overall clinicians had high ratings on the use of rule based approach, the 
need to optimize outcomes, the importance of taking the child’s views into account 
when making decisions and the value of psychosocial interventions subscales. 
Interestingly, the first three of these themes were remarkably absent from clinician’s 
accounts drawn from the previous open-ended interviews in the DRAMa study [27]. It 
is therefore still unclear as to whether clinicians truly ascribe value to a child-centered, 
guideline-based approach, which focuses on systematic practice and multiple steps in 
treatment to achieve the most favourable outcome for the child as possible. 
Alternatively, these types of questions may be susceptible to social desirability effects 
reflecting a discrepancy between what they report as being important and the values 
that they actually are applying to their clinical practice.  The high overall ratings on 
the rule based approach subscale suggest that clinicians in this sample, regardless of 
country of practice or professional affiliation (psychiatry or paediatrics/child 
neurology), believed that their medication-related decisions are currently informed by 
best practice, published guidelines [12, 14, 26]. The lowest mean scores were given to 
the focus on symptoms subscale, reflecting practice that is also in line with guidelines; 
clinicians are advised to assign greater weight to the broader impact of ADHD on the 
child’s functioning and levels of impairment, rather than applying standard symptom 
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counts to determine the effectiveness of a treatment. This accords with the growing 
focus on impairment as an outcome in clinical trials. Accordingly, clinicians in this 
study expressed views in line with current recommendations. Clinicians, however, 
were quite apprehensive about side effects and appeared uncertain about the value of 
long-term medication treatment and disinclined to pursue it. Thus, more studies about 
side effects of ADHD medication treatment, and the risk/benefit ratio, both in the 
short and longer term are required to inform clinicians view as current approaches 
may be too over-cautious.  
The intercorrelations between the IPAQ subscales suggested that the more clinicians 
gave importance to guidelines and a rule based approach, the more they were likely to have 
a positive view of psychosocial treatments, a higher sensitivity to side effects and reported 
feeling less influenced by external pressure. The more clinicians held a symptom-based 
approach, the less importance they were likely to place on psychosocial treatments. 
Psychosocial treatments were also of low importance to those who regarded long term 
medication treatment as favourable.    
Based on these patterns of association we identified four clinician profiles 
which we labeled as (i) pro-psychosocial, (ii) medication focused, (iii) unsystematic, 
and (iv) response optimisers. Remarkably, the first two clusters both assigned high 
ratings to guideline and rule-based approaches, but nevertheless showed a large 
discrepancy in their treatment preferences: Whereas roughly a quarter of the 
participants (cluster 1)  showed a clear preference for the use of psychosocial 
interventions, an equivalent proportion of clinicians (cluster 2) were distinctly 
medication oriented. Moreover, no relationship was found between country of 
practice and preference for medication or psychosocial inteventions suggesting this 
was not driven by differing guidelines, which may be more or less prevalent between 
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the UK and Europe. Either these two groups of professionals differentially interpreted 
the available guidelines, highlighting that published guidelines are not providing clear 
and straightforward direction for clinicians, or there is controversy amongst different 
available clinical guidelines, leaving room for individual interpretations and 
preferences. In practice, this may lead to individual patients receiving very different 
advice and recommendations based solely on inter-individual variation in treatment 
preferences of clinicians. Currently, the American Academy of Child and Adolescent 
Psychiatry practice parameter [16] and the European (Eunethydis network) guidelines 
[14, 28] consider both medication or psychosocial treatment as a first choice for mild 
to moderate cases and medication as a necessary first choice in severe cases. 
Conversely, the NICE guidelines [12] advocate that psychosocial treatment is always 
offered first in mild to moderate cases and that medication is only to be initiated when 
this fails or in the most severe (i.e. hyperkinetic disorder) cases. Accordingly, even 
when based on the same available empirical evidence, guideline producing 
committees do not always agree and therefore quite different attitudes in practice can 
be observed, all equally supported by evidence based medicine.  
 The pro-psychosocial cluster also clearly expressed a child-centered approach, 
with greater focus on the child’s views and involvement of the child in designing 
treatment plans, as well as a high sensitivity to side effects. This child-centered 
approach seems logical for those clinicians who favor psychosocial treatments, but 
may be equally important to consider for those favoring medication treatment, 
especially in the long term. Day-to-day adherence and long term persistence to a 
medication regimen have been shown to be relatively poor in ADHD treatment. Even 
in a well-managed trial, such as the Multimodal Treatment of Attention Deficit 
Hyperactivity Disorder (MTA) study, 25% of children who gave verbal reports of 
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medication adherence were found without any trace of medication in their saliva 
samples when tested [33]. The authors reported that, particularly from the age of 12 
years onwards, adherence to medication drops drastically with increasing age. 
Adolescents said they were less adherent because they felt fewer physical advantages 
of medication. They also reported more autonomy and responsibility for their 
medication schedule and therefore forgetfulness became more of an issue. Moreover, 
adolescents suffered more subjective side-effects of medication and were more fearful 
about brain effects, particularly in light of the incompatibility of their medication with 
alcohol and drugs [34]. Thus, it seems to be of great importance to build up a strong 
therapeutic relationship with the patient from an early age and repeatedly supply 
psycho-education at an age-adapted level, in order to further and fully engage the 
adolescents in continued treatment. Developing such relationships may mitigate 
against some of the poor outcomes reported for older adolescents and adults with 
ADHD [5].  
 The second group of clinicians in this study was characterized as medication 
focused. They reported the highest scores on the focus on symptoms subscale, 
reflecting treatment decisions that target symptom expression and causes rather than 
aiming to improve the child’s overall level of impairment or quality of life, as well as 
preferences for longer term courses of medication. Evidence for positive short term 
effects of stimulant medication for children with ADHD is consistently seen in 
clinical trials [35].  However, the empirical literature on the safety and long term 
effects of stimulant use is limited. A recent 10-year longitudinal study on 112 children 
with ADHD has reported compelling evidence for the long term use in the reduction 
of psychiatric impact of the condition [20]. Specifically, 73% of the group was in 
receipt of life-long courses of stimulants, and those taking the medication were 
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significantly less likely to develop major depression, conduct disorder, anxiety, and 
oppositional-defiant disorder. They were also less likely to repeat a year in school. In 
terms of academic achievement, several studies have shown a positive relationship 
between duration of treatment and academic outcome [36-38]. Conversely, other 
reports have suggested that the dopaminergic effects of stimulants may alter the 
structure and function of the brain [39, 40], and the long-term effects of this are 
unknown. Given this uncertainty it is quite understandable that clinicians have 
different attitudes to long-term use.   
A third group of clinicians were differentiated as ‘unsystematic’ by reporting 
medication related decisions that were least in line with clinical guidelines and 
evidence based practice. Guidelines strongly recommend that the treatment for 
ADHD must be based on an extensive diagnostic evaluation, i.e. the clinician should 
only start ADHD-treatment when the child meets the diagnostic criteria for ADHD 
[26]. Furthermore, when prescribing, contra-indications and dose-schedules should be 
carefully monitored and followed. Clinicians in this group had the lowest scores on 
the rule based approach  subscale. There were no other clear and consistent patterns 
of responses on any of the other subscales 
The final and largest group of clinicians in this study was characterised by the 
highest scores on the attitudes to optimising subscale, demonstrating that their 
treatment goals revolve around the greatest level of symptom reduction and 
functioning improvement as possible. Guidelines usually promote an active role for 
the clinician to strive for a systematic titration approach in which all possible doses 
are tried in order to evaluate the optimal outcome for the patient [14]. The level of 
active engagement required to ensure optimised outcomes may not always be possible, 
given the constraints and limitations of time and resources in everyday clinical 
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practice, as well as the need to ration service delivery and balance clinical priorities. 
Because of this, a balancing of costs of treatment (to the clinician and the state) and 
benefits to the patients and their family/community is necessary.  Moreover, clinicians 
may aim towards achieving “good enough” treatment, rather than optimal treatment, 
as long as patients (and their parents and teachers) are not actively in disagreement 
with the treatment plan, and in order to avoid using medication as a means to strive 
for perfection or ‘super normalization’. Accordingly, this group was also least likely 
to allow external sources of pressure, including teachers and parents, influence or alter 
their treatment decisions. 
Limitations 
 The IPAQ was a reliable and informative measure of clinicians’ prescription 
treatment attitudes for children with ADHD. However, the study is not without its 
limitations. The construction of the IPAQ was based on themes derived from a 
qualitative interview study conducted with many of the same clinicians who 
completed the questionnaire. Thus, the extent to which the IPAQ is generalisable to 
the views and attitudes of a wider population of prescribing clinicians remains 
unknown and requires replication with an independent group of participants. The 
validity of the questionnaire must also be established to clarify whether socially 
desirable responses were provided by respondents as seen through the discrepancies 
in responses given to the IPAQ rating scale in the current study versus the open-ended 
interview format used in Kovshoff et al [27]. Additionally, the small sample size 
warrants caution when interpreting the findings. In particular a larger sample is 
needed to confirm the psychometric integrity of the subscales and to study other 
elements of reliability and validity. 
Conclusions 
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 Pharmacological treatment of ADHD is common medical practice, but at 
present a wide variability in treatment practices is seen amongst individual clinicians. 
Thus, greater knowledge and awareness of the beliefs, views, and attitudes which 
govern these practices is warranted in order to understand this variability and reduce it 
in a direction that is compatible with evidence-based knowledge. The current data 
provide initial evidence about the factors that influence clinical decision making in 
this regard highlighting the considerable heterogeneity in approaches to medication in 
the sample studied. If the current results were replicated in a larger study they would 
be useful in both clinical training and the development of implementable guidelines. 
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Table 1 List of Items for Each IPAQ Subscale 
Subscale Name Items 
Optimising Outcomes My aim in treatment is to fully normalise ADHD 
behaviour. 
 
Not all symptoms necessarily have to disappear before I 
stabilize treatment.* 
 
I increase the dose of medication for ultimate 
improvement.  
 
I am only satisfied with treatment if symptoms are 
controlled across the whole day 
 
I am not satisfied with treatment unless all symptoms have 
improved. 
 
Rule-based approach 
 
It’s important that a patient has a formal diagnosis before 
starting medication. 
 
I carefully check for contra-indications before prescribing. 
  
I always carefully follow clinical guidelines when using 
medication.  
 
It is vital that parents follow the dose schedule precisely.
  
I am happy to try medication even when uncertain about 
the diagnosis.* 
 
Tolerance of side effects 
 
Treatment should be withdrawn if side effects emerge.* 
 
The emergence of common side effects does not alter my 
treatment plan.   
 
Concern about serious and uncommon side effects 
influences my prescribing practice.* 
Serious side effects are so rare that they are not an issue 
for me.   
I am concerned when any side effects of medication 
emerge.* 
Focus on symptoms Treating daily functioning is less important than treating 
ADHD. 
 
My goal is to reduce problems in daily living rather than 
normalise ADHD.* 
 
Improvement in a patient’s quality of life is the most 
important thing.*  
 
I am more likely to prescribe if I suspect that the ADHD 
has a biological cause.* 
 
My view of the cause of the ADHD in a patient does not 
influence my choice of treatment. 
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Influenced by external pressure 
 
Parents’ wishes influence my decisions to medicate .
   
It’s often hard to resist parental pressure to prescribe.  
 
If parents disagree with my decision to prescribe I will try 
hard to persuade them.* 
 
Teachers’ wishes influence my decision to medicate.  
 
I give my advice strongly when discussing medication 
with parents.*  
 
Importance of child’s views 
 
The child’s view about the need for medication is more 
important than the parents  
 
Children’s views influence my decision whether to 
medicate. 
 
Children’s views about medication are of little value.* 
  
I will use medication even if the child thinks he/she does 
not need it.* 
 
The adult’s view about medication overrides that of the 
child.* 
 
Long term meds The longer you can medicate a patient with ADHD the 
better.  
 
Long term medication should be avoided where possible.* 
 
I try to stop treating with medication as soon as possible.* 
 
I try to minimize long term exposure to medication.* 
 
I try to stop treating with medication as soon as the child 
reaches a certain age.* 
 
Positive views of psychosocial 
interventions 
Medication is the only really effective treatment for 
ADHD.* 
 
Psycho-social treatments should be used first before 
medication. 
 
The effectiveness of psycho-social treatments is often 
underestimated. 
 
I only use medication if psycho-social treatment has failed. 
 
I always want families to agree to psycho-social treatments 
alongside medication. 
Note. * indicates that the item must be reversed scored.  
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Table 2 Reliability of IPAQ Subscales 
 N Alpha 
Coefficient 
Optimising 
Outcome   
68 .72 
Rule-based approach 68 .75 
Tolerance of side effects 68 .63 
Focus on symptoms 68 .69 
Influenced by external pressure 68 .62 
Importance of child’s views 68 .78 
Long term meds 68 .63 
Positive views of psychosocial 
interventions 
68 .73 
 
Note. Alpha coefficients for the individual IPAQ Subscales 
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Table 3 IPAQ Subscale Scores for the Sample  
 Subscale Name N Mean (SD) Median Range 
 Optimising  
Outcomes 
68 19.00 (4.73) 18.80 9 – 28  
 Rule-based Approach 68 22.22 (4.82) 22.75 7 – 30  
 Tolerance of  
Side Effects 
68 10.85 (4.82) 11.25 0 – 21  
 Focus on  
Symptoms 
68 8.84 (4.11) 8.69 1 – 19  
 Influenced by  
External Pressure 
68 11.85 (4.75) 12.38 2 – 21 
 Importance of 
Child’s Views 
68 18.09 (4.87) 18.00 3 – 27  
 Long Term 
Medication 
68 13.15 (5.15) 12.67 2 – 24  
 Psychosocial  
Interventions 
68 16.85 (5.36) 16.85 4 – 30  
 
 
 
 
28 
 
Figure 1: Cluster Group Patterns on Each of the Eight IPAQ Subscales 
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Cluster 1: Pro Psychosocial (n=15)
Cluster 2: Medication Focused (n=18)
Cluster 3: Unsystematic (n=15)
Cluster 4: Response Optimisers (n=20)
 
 
Note. Figure 1 shows the findings from a cluster analysis of participant responses to questionnaire. Opt 
= Optimising Outcomes; Rule = Rule based approach; TolSideEf = Tolerance of side effects; FoS = 
Focus on Symptoms; ExtPres = Influenced by external pressure; ChildV = Importance of child’s views; 
LT meds = Long term medication; PsySoc = Psychosocial interventions. 
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Table 4 Significant Cluster Group Differences on IPAQ Subscales 
       
IPAQ Subscales 
 
F p Cluster  
Significantly 
higher or  
lower than 
  
   
Optimising 
 
7.22 p<.001 Cluster 4 > Cluster 1 Cluster 2 Cluster 3 
Systematic  
Approach 
31.20 p<.001 Cluster 3 < 
 
Cluster 1 Cluster 2 Cluster 4 
Tolerance of  
Side Effects 
10.65 p<.001 Cluster 1 < Cluster 2 Cluster 3  
Focus on  
Symptoms 
5.19 p=.003 Cluster 2 > Cluster 3   
Influenced by  
External Pressure 
8.51 p<.001 Cluster 4 <  Cluster 2 Cluster 3  
Importance of 
Child’s Views 
6.27 p =.001 Cluster 1 >  Cluster 2  Cluster 3 Cluster 4 
Long Term 
Medication 
20.42 p<.001 Cluster 2 > Cluster 1 Cluster 3 Cluster 4 
Psychosocial  
Interventions 
5.46 p = .002 Cluster 1 >  Cluster 2 Cluster 4  
Note. F and p values in table refer to analyses of variance (ANOVA) that compared cluster group scores and 
IPAQ subscale scores. 
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